RxDoctor Payments Data

Rhonna Lee

Primary Care · Spokane, WANPI 1780878017

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,818in general payments, 2019–2025

Across 445 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$725
  • GSK$630
  • Amgen$560
  • Novo Nordisk$541
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,767100%
  • Education$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie64$1,578
AstraZeneca37$1,124
Lilly USA, LLC29$725
GSK15$630
Amgen28$560
Novo Nordisk22$541
Johnson & Johnson13$531
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)16$528
Axsome Therapeutics, Inc.15$516
Otsuka America Pharmaceutical, Inc.15$415
Phathom Pharmaceuticals, Inc.6$337
Pfizer12$300
Lundbeck LLC14$269
Abbott6$268
Neurocrine Biosciences, Inc.3$253
Mayne Pharma Commercial LLC4$228
Corcept Therapeutics5$197
Radius Health, Inc.3$196
Novartis8$195
Boehringer Ingelheim6$189
Bayer4$180
Teva Pharmaceuticals USA, Inc.7$175
Kowa Pharmaceuticals America, Inc.12$170
Biohaven Pharmaceutical Holding Company Ltd.4$157
Dexcom, Inc.3$145
Takeda Pharmaceuticals U.S.A., Inc.7$137
Merck8$135
Ascendis Pharma Endocrinology Inc1$125
Ultragenyx Pharmaceutical Inc.1$125
E.r. Squibb & Sons, L.L.C.1$125
Antares Pharma, Inc.6$125
Astellas Pharma US Inc2$116
Alkermes, Inc.1$108
Boston Scientific4$100
Vanda Pharmaceuticals Inc.4$100
Biohaven Pharmaceuticals, Inc.5$93
Sanofi-aventis U.S. LLC4$91
Mylan Specialty L.p.4$86
Exact Sciences3$83
Esperion Therapeutics, Inc.4$78
Sunovion Pharmaceuticals Inc.5$77
Corium, LLC3$69
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$61
Verona Pharma, Inc.2$54
Hologic Sales And Service, LLC3$54
Supernus Pharmaceuticals, Inc.3$50
Amarin Pharma, Inc.3$48
Agile Therapeutics, Inc.2$38
Nevro Corp.1$33
Almatica Pharma LLC1$29
Recordati_rare_diseases_inc.1$26
Medtronic1$25
Idorsia Pharmaceuticals US Inc1$25
Impel Pharmaceuticals Inc.1$24
Daiichi Sankyo Inc.1$24
Sumitomo Pharma America, Inc.1$23
Organon1$22
Jazz Pharmaceuticals Inc.1$22
Medicure Pharma Inc.1$20
Stryker1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,818 in reported general payments places this provider in the 95th percentile of 94 primary care providers in Washington.

See all primary care providers in Washington

Medicare billing

Part B allowed, 2024
$35,573
Medicare patients
73
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$90,091
EliquisApixaban32$25,732
Nucynta ErTapentadol Hcl14$21,143
OzempicSemaglutide20$20,076
Bydureon BciseExenatide Microspheres16$15,958
TrulicityDulaglutide12$10,977
VascepaIcosapent Ethyl14$4,802
Gabapentin105$2,481
Omeprazole96$2,303
Albuterol Sulfate HfaAlbuterol Sulfate47$2,261
Roflumilast12$2,061
Levothyroxine Sodium194$1,833
Rosuvastatin Calcium151$1,628
Duloxetine Hcl62$1,400
Methylphenidate Hcl21$1,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,124$90,09193 claims
PfizerEliquis$300$25,73232 claims
Novo NordiskOzempic$541$20,07620 claims
Lilly USA, LLCTrulicity$725$10,97712 claims
AbbVieSynthroid$1,578$1,20714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 primary care providers in Washington.

Other primary care in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →